PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction

被引:184
作者
Abiko, Kaoru [1 ]
Mandai, Masaki [1 ]
Hamanishi, Junzo [1 ]
Yoshioka, Yumiko [1 ]
Matsumura, Noriomi [1 ]
Baba, Tsukasa [1 ]
Yamaguchi, Ken [1 ,2 ]
Murakami, Ryusuke [1 ]
Yamamoto, Ayaka [1 ]
Kharma, Budiman [1 ]
Kosaka, Kenzo [1 ]
Konishi, Ikuo [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto 6068507, Japan
[2] Japan Baptest Hosp, Dept Obstet & Gynecol, Kyoto, Japan
关键词
B7; FAMILY; IMMUNE PRIVILEGE; T-CELLS; EXPRESSION; B7-H1; CARCINOMA; SAFETY; MOLECULES; MECHANISM; APOPTOSIS;
D O I
10.1158/1078-0432.CCR-12-2199
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Ovarian cancer often progresses by disseminating to the peritoneal cavity, but how the tumor cells evade host immunity during this process is poorly understood. Programmed cell death 1 ligand 1 (PD-L1) is known to suppress immune system and to be expressed in cancer cells. The purpose of this study is to elucidate the function of PD-L1 in peritoneal dissemination. Experimental Design: Ovarian cancer cases were studied by microarray and immunohistochemistry. PD-L1 expression in mouse ovarian cancer cell line in various conditions was assessed by flow cytometry. PD-L1-overexpression cell line and PD-L1-depleted cell line were generated, and cytolysis by CTLs was analyzed, and alterations in CTLs were studied by means of timelapse and microarray. These cell lines were injected intraperitoneally to syngeneic immunocompetent mice. Results: Microarray and immunohistochemistry in human ovarian cancer revealed significant correlation between PD-L1 expression and peritoneal positive cytology. PD-L1 expression in mouse ovarian cancer cells was induced upon encountering lymphocytes in the course of peritoneal spread in vivo and coculture with lymphocytes in vitro. Tumor cell lysis by CTLs was attenuated when PD-L1 was overexpressed and promoted when it was silenced. PD-L1 overexpression inhibited gathering and degranulation of CTLs. Gene expression profile of CTLs caused by PD-L1-overexpressing ovarian cancer was associated with CTLs exhaustion. In mouse models, PD-L1 depletion resulted in inhibited tumor growth in the peritoneal cavity and prolonged survival. Conclusion: PD-L1 expression in tumor cell promotes peritoneal dissemination by repressing CTL function. PD-L1-targeted therapy is a promising strategy for preventing and treating peritoneal dissemination. Clin Cancer Res; 19(6); 1363-74. (C) 2012 AACR.
引用
收藏
页码:1363 / 1374
页数:12
相关论文
共 41 条
  • [1] Abrahams VM, 2003, CANCER RES, V63, P5573
  • [2] Malignant ascites - New concepts in pathophysiology, diagnosis, and management
    Aslam, N
    Marino, CR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (22) : 2733 - 2737
  • [3] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
    Blank, C
    Brown, I
    Peterson, AC
    Spiotto, M
    Iwai, Y
    Honjo, T
    Gajewski, TF
    [J]. CANCER RESEARCH, 2004, 64 (03) : 1140 - 1145
  • [4] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    Bookman, MA
    Darcy, KM
    Clarke-Pearson, D
    Boothby, RA
    Horowitz, IR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 283 - 290
  • [5] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [6] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    Brahmer, Julie R.
    Drake, Charles G.
    Wollner, Ira
    Powderly, John D.
    Picus, Joel
    Sharfman, William H.
    Stankevich, Elizabeth
    Pons, Alice
    Salay, Theresa M.
    McMiller, Tracee L.
    Gilson, Marta M.
    Wang, Changyu
    Selby, Mark
    Taube, Janis M.
    Anders, Robert
    Chen, Lieping
    Korman, Alan J.
    Pardoll, Drew M.
    Lowy, Israel
    Topalian, Suzanne L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3167 - 3175
  • [7] Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Curiel, TJ
    Coukos, G
    Zou, LH
    Alvarez, X
    Cheng, P
    Mottram, P
    Evdemon-Hogan, M
    Conejo-Garcia, JR
    Zhang, L
    Burow, M
    Zhu, Y
    Wei, S
    Kryczek, I
    Daniel, B
    Gordon, A
    Myers, L
    Lackner, A
    Disis, ML
    Knutson, KL
    Chen, LP
    Zou, WP
    [J]. NATURE MEDICINE, 2004, 10 (09) : 942 - 949
  • [8] Dong HD, 1999, NAT MED, V5, P1365
  • [9] Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
  • [10] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
    du Bois, Andreas
    Reuss, Alexander
    Pujade-Lauraine, Eric
    Harter, Philipp
    Ray-Coquard, Isabelle
    Pfisterer, Jacobus
    [J]. CANCER, 2009, 115 (06) : 1234 - 1244